Nonalcoholic fatty liver disease (NAFLD), a common cause of chronic liver disease (CLD), has a global prevalence of 25%. (1) Its progressive form, nonalcoholic steatohepatitis (NASH), is a leading indication for liver transplantation (LT) in the United States. (2,3) As a result, specialty societies, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver, have developed guidance on the epidemiology, diagnosis, and treatment of NAFLD and NASH. (4,5) Therefore, the transplant team must be well versed in the state of current knowledge about NAFLD and transplant-specific issues for this increasingly important indication for LT.
NAFLD spans a clinic-pathologic spectrum characterized by hepatic steatosis with or without other pathologic features and in the absence of other specific causes of fatty liver. (4, 6) Although NAFLD is diagnosed by liver biopsy or radiologic assessment, the diagnosis of the NAFLD subtype of NASH requires a liver biopsy with strict pathologic criteria. The term "nonalcoholic" denotes exclusion of excessive alcohol consumption and other causes of liver disease. In recent NAFLD studies, this threshold is >21 and >14 standard drinks per week for men and women, respectively. (4) There is evidence that the NAFLD prevalence in the US population is approximately 23.5%, with NASH prevalence estimated between 1.5% and 6.5%. (1, 7) The pooled estimated incidence rates for NAFLD from Asia and the West are 52.3 per 1000 person-years (95% confidence interval [CI], 28.3-96.8) and 28 per 1000 person-years (95% CI, 19.3-40.6), respectively. (1, 4) The majority of NAFLD and NASH patients have metabolic comorbidities (ie, obesity, type 2 diabetes mellitus [T2DM], and dyslipidemia), whereas a small proportion have "lean" NAFLD. In the United States, the prevalence of lean NAFLD was reported to be 7%, whereas in rural areas of some Asian countries, it can be as high as 25%. (1, 8, 9) The majority of NAFLD worldwide is related to metabolic comorbidities, suggesting this association is bidirectional. Metabolic comorbidities are risk factors for NAFLD and NASH, whereas the prevalence of NAFLD and NASH is high in patients with metabolic comorbidities. In a recent meta-analysis of patients with diabetes, the prevalence of NAFLD was 57.8% (95% CI, 53.9%-61.6%), whereas the Abbreviations: AASLD, American Association for the Study of Liver Diseases; CI, confidence interval; CKD, chronic kidney disease; CLD, chronic liver disease; CVD, cardiovascular disease; ELF, enhanced liver fibrosis; FDA, Food and Drug Administration; GLP-1, glucagon-like peptide-1; HCC, hepatocellular carcinoma; LT, liver transplantation; MRE, magnetic resonance elastography; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NFS, nonalcoholic fatty liver disease fibrosis score; T2DM, type 2 diabetes mellitus. prevalence of NASH was 65.3% (95% CI, 51.7%-76.7%), and the prevalence of advanced fibrosis (fibrosis F3) was 15.1% (95% CI, 8.2%-26.1%). (10) In addition to T2DM, most morbidly obese patients undergoing bariatric surgery have NAFLD, 20%-30% have NASH, and 10% have advanced fibrosis. (11) In the United States, there is some impact of ethnicity on the prevalence and progressiveness of NAFLD. In this context, Hispanics have a higher prevalence of NAFLD, whereas African Americans have lower prevalence rates, potentially due to the genetic variation in the patatin-like phospholipase domain-containing 3 gene. (4, 6) Progression of NAFLD Patients with histologic NASH, especially those with some degree of fibrosis, are at greatest risk for progression to cirrhosis and liver-related mortality. (6) The most common cause of death in NAFLD and NASH patients, however, is cardiovascular disease (CVD) with liver-related mortality among the top 3. (4, 6) To quantify liver-related and overall mortality rates, a meta-analysis suggested these rates among NAFLD and NASH to be 0.8 per 1000 (range, 0.3-1.8) and 11.8 per 1000 (range, 7.1-19.5) person-years and 15.4 per 1000 (range, 11.7-20.3) and 25.6 per 1000 (range, 6.3-103.8) person-years, respectively. (1) With an increasing number of patients with cirrhosis, NAFLD has become one of the most common underlying causes of hepatocellular carcinoma (HCC) and the second/third most common indication for LT. (4) These data reflect the role of progressive NAFLD (NASH) in the increase in patients with HCC and those listed for LT. (2, 3) Despite this progressive potential, progression of NASH is nonlinear with some progressing and others spontaneously regressing. (6) This complex pattern requires diagnostic and prognostic noninvasive biomarkers that can help clinicians identify patients who are at the highest risk for progressive liver disease.
Clinically, NAFLD patients with components of metabolic comorbidities are at greatest risk for progression. (10, (12) (13) (14) Additionally, patients whose liver biopsies show fibrosis stage 2 are especially at risk for liver-related mortality. (15, 16) Some patients with metabolic comorbidities may not meet the pathologic criteria for NASH such as those with cryptogenic cirrhosis or those with severe steatofibrosis. (4, 17) Both groups are excluded from NASH clinical trials while experiencing poor longterm prognosis, similar or worse than NASH cirrhosis. (17) In clinical practice, all these patients with advanced fibrosis should be considered in a similar fashion.
Diagnostics and Treatment of NASH
Liver biopsy remains the most accurate technique for identifying steatohepatitis and fibrosis staging, albeit limited by cost, sampling error, and procedure-related morbidity and mortality. (4, 6, 7, 17) Noninvasive tests like serum aminotransferase and routine imaging modalities such as ultrasound, computerized tomography, and magnetic resonance imaging cannot distinguish NASH from non-NASH, nor stage hepatic fibrosis. (4, 6, 7, 17) Other methods including clinical prediction rules (eg, nonalcoholic fatty liver disease fibrosis score [NFS], FIB-4 index, aspartate aminotransferase-toplatelet ratio index), noninvasive serum-based tests (eg, enhanced liver fibrosis [ELF] panel, Fibrometer, FibroTest, Hepascore), or image-based tests (eg, transient elastography, magnetic resonance elastography [MRE], acoustic radiation force impulse imaging, supersonic shear wave elastography) are used to stage the severity of liver disease. (4, 6, 17) A noninvasive test with optimal receiver operating curve is not available, so a combination of these noninvasive biomarkers can increase the predictive performance of these algorithms. (6, 17) Among these tests, NFS, ELF, and MRE provide the most valuable tools in clinical practice. Nevertheless, in 2017, the Food and Drug Administration (FDA) still requires histologic end points for clinical trials. (17) Given that this is a dynamic field, there is a rush to identify and validate a noninvasive test for NASH or NASH with fibrosis (4, 6, 7, 17) for FDA approval.
At present, interventions for NAFLD have focused on mitigating the associated metabolic comorbidities. (4, 7, 17) The AASLD guidance document suggests that weight loss can be best achieved through a combination of a low-calorie (500-1000 kcal) diet and moderate-intensity exercise. A 3%-5% weight loss is necessary to improve steatosis, but a 7%-10% weight loss is necessary to improve histopathologic features of NASH, including fibrosis. Exercise alone in NAFLD can improve or prevent hepatic steatosis, but the impact of exercise on hepatic necroinflammation or fibrosis is not well studied. (4, 7, 17) Lifestyle modifications are recommended for all NAFLD patients due to cardio-metabolic benefits, but treatment with drugs should be limited to those with progressive liver disease such as steatohepatitis and/or fibrosis. Given the association of NASH with insulin resistance, metformin, pioglitazone, and glucagon-like peptide-1 (GLP-1) agonists have received more attention. Currently, the evidence does not support the use of metformin for treating NASH. (4, 6) Although pioglitazone does improve liver histology in patients with biopsy-proven NASH, its use should be limited to diabetic patients with NASH whose risks and benefits have been explored. (18) The AASLD guidance document indicates that it is premature to use GLP-1 agonists to treat NASH. (4) Antioxidants targeting the potential oxidative stress in patients with NASH have shown promise. The AASLD guidance document suggests that vitamin E (rrr a-tocopherol) administered at a daily dose of 800 IU/day can improve liver histology in nondiabetics with biopsy-proven NASH. (4, 6) Again, risks and benefits of longterm use of this drug should be considered. The guidance document emphasizes that vitamin E is not recommended to treat NASH in diabetic patients, NAFLD without liver biopsy, NASH cirrhosis, or cryptogenic cirrhosis. (4, 6) Other drugs such as ursodeoxycholic acid, probiotics, and betaine are not recommended for the treatment of NAFLD or NASH due to lack of supporting evidence. (4, 6) Finally, omega-3 fatty acids or statins should not be used to treat NASH, (4) but they can be used to treat dyslipidemia in these patients. (6) Finally, there are over 2 dozen phase 2 clinical trials of new agents for treatment of NASH and 4 ongoing phase 3 clinical trials of agents, such as obeticholic acid, elafibranor, selonsertib, and cenicriviroc that are being carried out in multicenter, multinational clinical trials. (6, 19) Metabolic or bariatric surgery reverses or improves complications of metabolic comorbidities. Foregut bariatric surgery is used for obese individuals with NAFLD or NASH, but it is premature to recommend this surgery as an established treatment for NASH. (20) Furthermore, the type, safety, and efficacy of bariatric surgery in obese individuals with established NASHcirrhosis should be considered on a case-by-case basis by an experienced surgical-hepatology team.
As noted previously, patients with NAFLD are at high risk for cardiovascular morbidity and mortality. (1) Because statins do not pose a serious "hepato-toxic" risk to patients with NAFLD and NASH, these drugs can be used to treat dyslipidemia even in those with cirrhosis. In contrast, their use should be avoided in NASH patients with decompensated cirrhosis. (4, 21) LT in Patients with NASH Over the past two decades, there has been an increasing recognition that cryptogenic cirrhosis in the United States represents burnt-out NASH. (1) (2) (3) In this context, NASH and cryptogenic cirrhosis have been increasingly seen among patients awaiting LT. (2, 3) Transplant candidates with NASH typically have several metabolic comorbidities added to the complexity of managing the complications of CLD. Obesity increases the risk of decompensation while awaiting LT and can present a surgical technical challenge (4) although an upper limit body mass index to LT has not been defined. In contrast, pretransplant weight reduction through diet and exercise followed by successful LT has been reported. (4) Additionally, bariatric surgery with sleeve gastrectomy pre-LT has been reported although the safety and efficacy of this intervention have not been established. (4) Although it seems counterintuitive, obese patients with NASH also suffer from sarcopenia, a predictor of posttransplant adverse outcomes. (4) In this context, pre-LT nutritional assessment and supplementation are important. (4) Finally, pretransplant assessment of NASH or cryptogenic cirrhosis patients for CVD will be important. In fact, noninvasive functional cardiac testing (such as dobutamine stress echocardiography) is recommended in patients with NASH cirrhosis, whereas those with abnormal/unequivocal results may require coronary angiography. In addition to CVD, patients with NASH are at risk for chronic kidney disease (CKD) and assessment of renal function may not always be easily assessed by estimating the glomerular filtration rate or serum creatinine level. (4) 
Issues After LT in Patients with NASH
Despite metabolic comorbidities, posttransplant outcomes of NASH patients are generally good. In fact, 1-, 3-, and 5-year patient and graft survival rates are generally good and similar to other liver diseases. (4, 10) NAFLD and NASH can recur following LT, (21, 22) while NASH with significant fibrosis (stage 2) occurs in approximately 5% of recipients by 5 years after transplantation. (4) Persistence of metabolic comorbidities in these recipients after LT is very common. (10) In addition to weight management, there are a number of important pharmacological considerations related to these metabolic comorbidities in post-LT NASH. It is important to note that calcineurin inhibitors and corticosteroids can exacerbate T2DM. (4) Furthermore, hypertension, dyslipidemia, and CVD risk and renal insufficiency can all be worsened due to specific immunosuppressive regimens. Therefore, it is critical not only to manage the metabolic complications in these patients but also to pay special attention to the adverse effects of immunosuppressive agents and other drugs used in the post-LT setting. (23, 24) 
Summary
The AASLD guidance document for NAFLD and NASH is intended to provide current management advice on transplant-specific issues. Although progression rates for NASH are slower than HCV, given the number of patients at risk for NASH, this disease is now the most common cause of CLD and increasingly HCC in the United States. NASH patients on the transplant list have metabolic comorbidities that are difficult to manage. They also have extrahepatic complications, such as CVD and CKD, which increase their morbidity and mortality. Although posttransplant outcomes seem to be similar to other indications, management of these metabolic comorbidities is a challenge. Severe recurrence and progression of NASH and cirrhosis posttransplantation are uncommon. Given the interactions between metabolic comorbidities of NASH and the adverse effects of immunosuppressive agents, post-LT management can be further complicated. This requires diligent attention to details to minimize adverse effects, to treat and prevent the metabolic comorbidities as well as the extrahepatic complications such as CVD and CKD. These pretransplant and posttransplant issues must be recognized by the transplant team who will be intimately and increasingly involved in the management of this rising patient population in the United States and the rest of the world.
